Skip to main content

Human Kallikrein 14 Biotinylated Antibody

R&D Systems, part of Bio-Techne | Catalog # BAF2626

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
BAF2626

Key Product Details

Species Reactivity

Human

Applications

ELISA Detection (Matched Antibody Pair), Western Blot

Label

Biotin

Antibody Source

Polyclonal Goat IgG

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant human Kallikrein 14
Gln19-Met248, predicted
Accession # AAD50773

Specificity

Detects human Kallikrein 14 in ELISAs and Western blots. In sandwich immunoassays, less than 0.05% cross-reactivity with recombinant human KLK1, 3, 4, 5, 7, 8, 11, 12, and 13 is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Applications for Human Kallikrein 14 Biotinylated Antibody

Application
Recommended Usage

Western Blot

0.1 µg/mL
Sample: Recombinant Human Kallikrein 14 (Catalog # 2626-SE)

Human Kallikrein 14 Sandwich Immunoassay

ELISA Detection (Matched Antibody Pair)
Recommended Concentration: 0.1-0.4 µg/mL
Use in combination with these reagents:
  • Detection Reagent: Human Kallikrein 14 Antibody (Catalog # AF2626)
  • Standard: Recombinant Human Kallikrein 14 Protein, CF (Catalog # 2626-SE)
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Kallikrein 14

Human tissue kallikreins refer to a group of secreted serine proteases that are encoded by homologous genes clustering on chromosome 19q13.3-4. As a member of this family, human tissue Kallikrein 14 (hKLK14) is present in many tissues, with high levels in breast, skin, prostate, and brain. The 251 amino acid hKLK14 precursor consists of a signal peptide (residues 1 to 18), a pro peptide (residues 19 to 24) and an active protein (residues 25 to 251) (1). Its enzymatic activity has been shown to be mainly trypsin-like (2). However, its physiological substrates and functions are still unclear. Several studies have suggested that hKLK14 may have clinical utility as a biomarker for cancer of the breast, ovary, and prostate (3, 4). In addition, it may be the initiator of a kallikrein proteolytic cascade responsible for the degradation of the adhesion structures in the stratum corneum (2). The purified, secreted rhKLK14 corresponds to the pro form (residues 19 to 248) with a replacement of the last three residues with a His tag at the C-terminus. When activated by thermolysin, it displays enzymatic activity towards a fluorogenic peptide described above. This activity can be inhibited by rhSerpin A4, E1, and F2 (R&D Systems, Catalog # 1669-PI, 1786-PI, and 1470-PI, respectively).

References

  1. Yousef, G. M. et al. (2001) Cancer Res. 61:3425.
  2. Brattsand, M. et al. (2004) J. Invest. Dermatol. 124:198.
  3. Borgono, C. et al. (2003) Cancer Res. 63:9032.
  4. Yousef, G. M. et al. (2003) Prostate. 56:287.

Alternate Names

KLK14

Entrez Gene IDs

43847 (Human)

Gene Symbol

KLK14

UniProt

Additional Kallikrein 14 Products

Product Documents for Human Kallikrein 14 Biotinylated Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human Kallikrein 14 Biotinylated Antibody

For research use only

Loading...
Loading...
Loading...
Loading...